Artes Medical, Inc. (Nasdaq:ARTE), a medical aesthetics company whose product ArteFill® is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of "smile line" wrinkles, announced that it will release its financial results for the quarter ended June 30, 2008 on Monday, August 11, 2008 at close of market.
Artes Medical will host a webcast and conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on August 11, 2008 to discuss the financial results. The dial in numbers are (800) 659-2032 for domestic callers, and (617) 614-2712 for international callers. The passcode for both domestic and international callers is 17928698. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.artesmedical.com. Participating in the call will be Christopher J. Reinhard, Executive Chairman and Michael K. Green, Chief Financial Officer.
After the live web cast the call will remain available on Artes Medical's web site for at least 30 days following presentation. In addition, a telephonic reply of the call will be available for 7 days. The replay dial-in numbers are (888) 286-8010 for domestic callers, and (617) 801-6888 for international callers. The passcode for both domestic and international callers is 87813533.
About Artes Medical, Inc.
Artes Medical is a medical aesthetics company focused on developing, manufacturing and commercializing a new and innovative medical aesthetic products including injectable products for the dermatology and plastic surgery markets. The Company’s initial product, ArteFill, is being marketed to men and women as a treatment option for the correction of nasolabial folds. Additional information about Artes Medical and ArteFill is available at www.artesmedical.com and www.artefill.com.
Forward-Looking Statements
This news release contains forward-looking statements that are based on the Company’s current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, which include the Company’s history of net losses, its ability to timely raise additional funds to support its operations, its ability to manage its operating expenses, its reliance on its sole FDA-approved product, ArteFill, its limited experience in commercializing ArteFill, its future receipt of FDA approval to extend the efficacy period of ArteFill beyond six months and eliminate the skin test requirement, and the risk that the Company’s revenue projections may prove incorrect because of unexpected difficulty in generating sales and market acceptance of ArteFill, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. A more extensive set of risks and uncertainties is set forth in the Company’s SEC filings available at www.sec.gov. These forward-looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.
Artes Medical® and ArteFill® are registered trademarks of Artes Medical, Inc.
Contacts:
Manning Selvage & Lee
Kelley
Childrey, 323-866-6003
kelley.childrey@mslpr.com
or
Investor
Relations:
Artes Medical
Cheryl Monblatt Allen,
858-550-9999
callen@artesmedical.com
